PoliticsSeptember 29 at 07:07 AM

UniQure’s (QURE) Gene therapy continues to slow Huntington’s progression after four years, but the magnitude of the treatment’s benefit waned compared to a similar analysis from a year ago, reports StatNews

StockNow breaking-news AI analysis

UniQure's gene therapy slowed Huntington's progression at four years, though its benefit waned versus year-three data, following recent regulatory filings in the U.S. and U.K.

1 stocks

QUREuniQure N.V.$18.31Current price

What do investors think?

Curious what other investors think?Log in to see reactions and join the conversation.

StockNow uses AI to translate and analyze information and does not guarantee its accuracy or completeness.

Today's market highlights

A selection of stories drawing attention in the market.

Geopolitics

UKMTO notes of a report in the evening of September 28th; says a vessel was struck by an unknown projectile in the Strait of Hormuz; vessel is underway after a resulting fire was extinguished, with the crew safe.

Geopolitics

US President Trump backs Russia sanctions relief on prisoner release, Atlantic reports; Trump expressed support for the plan a few months ago

FX/Bonds